Stella Pharma Statistics
Total Valuation
Stella Pharma has a market cap or net worth of JPY 10.75 billion. The enterprise value is 8.63 billion.
| Market Cap | 10.75B |
| Enterprise Value | 8.63B |
Important Dates
The next estimated earnings date is Friday, November 7, 2025.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Stella Pharma has 34.03 million shares outstanding. The number of shares has increased by 8.66% in one year.
| Current Share Class | 34.03M |
| Shares Outstanding | 34.03M |
| Shares Change (YoY) | +8.66% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 4.28% |
| Owned by Institutions (%) | 7.73% |
| Float | 20.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.84 |
| PB Ratio | 3.53 |
| P/TBV Ratio | 3.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -63.94 |
| EV / Sales | 8.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.66, with a Debt / Equity ratio of 0.24.
| Current Ratio | 21.66 |
| Quick Ratio | 15.84 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.00 |
Financial Efficiency
Return on equity (ROE) is -4.69% and return on invested capital (ROIC) is -1.27%.
| Return on Equity (ROE) | -4.69% |
| Return on Assets (ROA) | -0.94% |
| Return on Invested Capital (ROIC) | -1.27% |
| Return on Capital Employed (ROCE) | -1.55% |
| Revenue Per Employee | 23.07M |
| Profits Per Employee | -3.14M |
| Employee Count | 43 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 0.10 |
Taxes
In the past 12 months, Stella Pharma has paid 2.00 million in taxes.
| Income Tax | 2.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.37% in the last 52 weeks. The beta is 0.91, so Stella Pharma's price volatility has been similar to the market average.
| Beta (5Y) | 0.91 |
| 52-Week Price Change | -30.37% |
| 50-Day Moving Average | 372.14 |
| 200-Day Moving Average | 396.25 |
| Relative Strength Index (RSI) | 37.87 |
| Average Volume (20 Days) | 425,800 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Stella Pharma had revenue of JPY 992.00 million and -135.00 million in losses. Loss per share was -3.97.
| Revenue | 992.00M |
| Gross Profit | 871.00M |
| Operating Income | -75.00M |
| Pretax Income | -133.00M |
| Net Income | -135.00M |
| EBITDA | -41.25M |
| EBIT | -75.00M |
| Loss Per Share | -3.97 |
Balance Sheet
The company has 2.85 billion in cash and 726.00 million in debt, giving a net cash position of 2.12 billion or 62.38 per share.
| Cash & Cash Equivalents | 2.85B |
| Total Debt | 726.00M |
| Net Cash | 2.12B |
| Net Cash Per Share | 62.38 |
| Equity (Book Value) | 3.05B |
| Book Value Per Share | 89.63 |
| Working Capital | 4.67B |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 87.80%, with operating and profit margins of -7.56% and -13.61%.
| Gross Margin | 87.80% |
| Operating Margin | -7.56% |
| Pretax Margin | -13.41% |
| Profit Margin | -13.61% |
| EBITDA Margin | -4.16% |
| EBIT Margin | -7.56% |
| FCF Margin | n/a |
Dividends & Yields
Stella Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.66% |
| Shareholder Yield | -8.66% |
| Earnings Yield | -1.26% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Stella Pharma has an Altman Z-Score of 5.7 and a Piotroski F-Score of 4.
| Altman Z-Score | 5.7 |
| Piotroski F-Score | 4 |